Viking Therapeutics Inc. (VKTX)
25.68
1.77 (7.40%)
At close: Apr 02, 2025, 3:59 PM
24.00
-6.52%
After-hours: Apr 02, 2025, 07:58 PM EDT
Viking Therapeutics Income Statement
Financials in USD. Fiscal year
is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | n/a | 292K | 291K | 296K | 277K | 260K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross Profit | n/a | -292K | -291K | -296K | -277K | -260K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Income | -150.92M | -100.83M | -70.36M | -55.68M | -42.66M | -32.69M | -26.16M | -19.07M | -13.85M | -12M | -23.47M | -101.08K | -438.56 |
| Interest Income | n/a | 15.02M | 1.59M | 703K | 3.23M | 7.05M | 3.24M | 1.27K | n/a | n/a | n/a | n/a | 5.54 |
| Pretax Income | -109.96M | -85.89M | -68.87M | -54.99M | -39.49M | -25.78M | -22.06M | -20.58M | -14.73M | -23.4M | -21.88M | -146.25K | -444.11 |
| Net Income | -109.96M | -85.89M | -67.38M | -54M | -36.05M | -25.78M | -22.06M | -20.58M | -14.73M | -23.4M | -21.88M | -146.25K | -444.11 |
| Selling & General & Admin | 49.28M | 37.02M | 16.12M | 10.7M | 10.73M | 9.13M | 7.12M | 5.33M | 4.85M | 5.03M | 1.24M | 89.46K | 163.08 |
| Research & Development | 101.64M | 63.81M | 54.23M | 44.98M | 31.93M | 23.56M | 19.04M | 13.74M | 9M | 6.97M | 22.22M | 11.61K | 275.48 |
| Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 1.4M | 344.93K | 1.06M | -10.43M | 2.21M | -20.62K | n/a |
| Operating Expenses | 150.92M | 100.83M | 70.36M | 55.68M | 42.66M | 32.69M | 26.16M | 19.07M | 13.85M | 12M | 23.47M | 101.08K | 438.56 |
| Interest Expense | n/a | 88K | n/a | 18K | 106K | 146K | 404K | 1.28M | 1.81M | 982.18K | 628.68K | 24.55K | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | n/a | 100.83M | 70.36M | 55.68M | 42.66M | 32.69M | 26.16M | 19.07M | 13.85M | 12M | 23.47M | 101.08K | 438.56 |
| Income Tax | n/a | n/a | -1.49M | -988K | -3.44M | 6.99M | -2.71M | 1.85M | 1.95M | 982.18K | 628.68K | 24.55K | -5.54 |
| Shares Outstanding (Basic) | 109.04M | 94.35M | 76.83M | 77.2M | 72.6M | 71.96M | 57.58M | 25.98M | 16.28M | 6.36M | 4.31M | 4.31M | 1.48K |
| Shares Outstanding (Diluted) | 109.04M | 94.35M | 76.83M | 77.2M | 72.6M | 71.96M | 57.58M | 25.98M | 16.28M | 6.36M | 4.31M | 4.31M | 1.48K |
| EPS (Basic) | -1.01 | -0.91 | -0.88 | -0.7 | -0.5 | -0.36 | -0.38 | -0.79 | -0.9 | -3.68 | -5.08 | -0.03 | -0.3 |
| EPS (Diluted) | -1.01 | -0.91 | -0.88 | -0.7 | -0.5 | -0.36 | -0.38 | -0.79 | -0.9 | -3.68 | -5.08 | -0.03 | -0.3 |
| EBITDA | -150.92M | -100.83M | -70.36M | -55.39M | -42.66M | -25.37M | 4.66M | 442.88K | 1.15M | -22.39M | -21.26M | -121.7K | -109.64K |
| EBIT | n/a | -100.83M | -70.36M | -55.68M | -42.66M | -25.63M | -21.5M | -18.63M | -12.7M | -22.39M | -23.47M | -121.7K | -109.64K |
| Depreciation & Amortization | n/a | 292K | 291K | 296K | 277K | 260K | 26.16M | 19.07M | 13.85M | -10.43M | 2.21M | -20.62K | 438.56 |